ProQR Therapeutics (PRQR) Lowered to “Buy” at BidaskClub

BidaskClub downgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a strong-buy rating to a buy rating in a report published on Thursday morning.

PRQR has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of ProQR Therapeutics from a hold rating to a sell rating in a report on Saturday, October 13th. ValuEngine downgraded shares of ProQR Therapeutics from a strong-buy rating to a buy rating in a report on Thursday, August 30th. HC Wainwright restated a buy rating and set a $20.00 price target on shares of ProQR Therapeutics in a report on Tuesday, October 30th. Chardan Capital restated a buy rating and set a $9.00 price target on shares of ProQR Therapeutics in a report on Monday, August 13th. Finally, Evercore ISI assumed coverage on shares of ProQR Therapeutics in a report on Tuesday, September 18th. They set an outperform rating and a $35.00 price target for the company. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $18.00.

Shares of NASDAQ PRQR traded down $1.44 during midday trading on Thursday, reaching $19.08. 176,647 shares of the stock were exchanged, compared to its average volume of 205,090. The company has a market capitalization of $817.59 million, a P/E ratio of -9.84 and a beta of 0.54. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.02 and a quick ratio of 4.02. ProQR Therapeutics has a twelve month low of $2.75 and a twelve month high of $24.00.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.10. As a group, research analysts expect that ProQR Therapeutics will post -1.38 EPS for the current year.

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its position in shares of ProQR Therapeutics by 519.0% during the 1st quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 28,025 shares during the period. Ardsley Advisory Partners purchased a new position in shares of ProQR Therapeutics during the 2nd quarter worth approximately $365,000. Essex Investment Management Co. LLC purchased a new position in shares of ProQR Therapeutics during the 2nd quarter worth approximately $604,000. Franklin Street Advisors Inc. NC boosted its position in shares of ProQR Therapeutics by 50.0% during the 2nd quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock worth $657,000 after purchasing an additional 30,000 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of ProQR Therapeutics during the 2nd quarter worth approximately $1,426,000. 28.55% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Featured Story: Conference Calls

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply